El Déficit de Vitamina D y su influencia en el cáncer de mama

Vitamin D Deficiency and its influence on breast cancer

  • Manuela Rus Valero Hospital Universitario Ramón y Cajal (Madrid, España)
  • Luisa María Rus Valero Hospital San Juan de la Cruz (Úbeda, España)
Palabras clave: Vitamina D, Déficit de vitamina D, Cáncer de mama, 25 (OH) D, Cáncer triple negativo, Riesgo, Mortalidad
Key-words: Vitamin D, Vitamin D deficiency, Breast cancer, 25 (OH) D, Triple negative cancer, Risk and mortality

Resumen

Abstract

Bibliografía

1. Gilaberte Y, Aguilera J, Carrascosa JM, Figueroa FL, Romaní De Gabriel J, Nagore E. Vitamin D: Evidence and controversies. Actas Dermosifiliogr. 2011;102(8):572–88.
2. Jones G. The discovery and synthesis of the nutritional factor vitamin D. Int J Paleopathol. 2018;23(October 2017):96–9.
3. Masvidal Aliberch RM, Ortigosa Gómez S, Baraza Mendoza MC, Garcia-Algar O. Vitamina D: fisiopatología y aplicabilidad clínica en pediatría [Vitamin D: pathophysiology and clinical applicability in paediatrics]. An Pediatr (Barc). 2012;77(4):279.e1-279.e10. doi:10.1016/j.anpedi.2012.05.019
4. Gil Á, Plaza-Diaz J, Mesa MD. Vitamin D: Classic and Novel Actions. Ann Nutr Metab. 2018;72(2):87–95.
5. Rodríguez-Rodríguez E, Aparicio A, Sánchez-Rodríguez P, Lorenzo-Mora AM, López-Sobaler AM, Ortega RM. Vitamin D deficiency in Spanish population. Importance of egg on nutritional improvement. Nutr Hosp. 2019;36(Ext3):3–7.
6. Lope V, Castelló A, Mena-Bravo A, Amiano P, Aragonés N, Fernández-Villa T, et al. Serum 25-hydroxyvitamin D and breast cancer risk by pathological subtype (MCC- Spain). J Steroid Biochem Mol Biol. 2018; 182:4–13.
7. O’Brien KM, Sandler DP, Taylor JA, Weinberg CR. Serum vitamin D and risk of breast cancer within five years. Environ Health Perspect. 2017; 125(7):1–9.
8. Buono G, Giuliano M, De Angelis C, Lauria R, Forestieri V, Pensabene M, et al. Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study. Clin Breast Cancer. 2017; 17(7):559– 63.
9. Park S, Lee DH, Jeon JY, Ryu J, Kim S, Kim JY, et al. Serum 25-hydroxyvitamin D deficiency and increased risk of breast can-cer among Korean women: a case–control study. Breast Cancer Res Treat. 2015; 152(1):147–54.
10. Chen P, Li M, Gu X, et al. Higher blood 25(OH)D level may reduce the breast cancer risk: evidence from a Chinese population based case-control study and meta-analysis of the observational studies. PLoS One. 2013;8(1):e49312. doi:10.1371/journal.pone.0049312
11. Bilinski K, Boyages J. Association between 25-hydroxyvitamin D concentration and breast cancer risk in an Australian popu-lation: An observational case-control study. Breast Cancer Res Treat. 2013; 137(2):599–607.
12. Yao S, Sucheston LE, Millen AE, et al. Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prog-nostic characteristics: a case-control and a case-series study. PLoS One. 2011;6(2):e17251. doi:10.1371/journal.pone.0017251
13. Thanasitthichai S, Prasitthipayong A, Boonmark K, Purisa W, Guayraksa K. Negative impact of 25-hydroxyvitamin D defi-ciency on breast cancer survival. Asian Pacific J Cancer Prev. 2019; 20(10):3101–6.
14. Madden JM, Murphy L, Zgaga L, Bennett K. De novo vitamin D supplement use post-diagnosis is associated with breast cancer survival. Breast Cancer Res Treat. 2018; 172(1):179–90.
15. Ismail A, El-Awady R, Mohamed G, Hussein M, Ramadan SS. Prognostic significance of serum Vitamin D levels in Egyptian females with breast cancer. Asian Pacific J Cancer Prev. 2018; 19(2):571–6.
16. Yao S, Kwan ML, Ergas IJ, Roh JM, Cheng TD, Hong C, et al. Higher serum levels of vitamin D at diagnosis are associated with better survival in a prospective cohort of 1,666 women with breast cancer: A case-cohort analysis in the Pathways Study. JAMA Oncol. 2017; 3(3):351–7.
17. Villaseñor A, Ballard-barbash R, Ambs A, Bernstein L, Baumgartner R, Ulrich CM, et al. breast cancer survivors. 2014; 24(4):759–67.
18. Hatse S, Lambrechts D, Verstuyf A, Smeets A, Brouwers B, Vandorpe T, et al. Vitamin D status at breast cancer diagnosis: Correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis. 2012; 33(7):1319–26.
19. Study LW, Jacobs ET, Thomson CA, Flatt SW, Al-delaimy WK, Hibler EA, et al. Vitamin D and breast cancer recurrence in the Women ’ s Healthy Eating. Am J Clin Nutr. 2011; 25(2):108–17.
20. Vrieling A, Seibold P, Johnson TS, Heinz J, Obi N, Kaaks R, et al. Circulating 25- hydroxyvitamin D and postmenopausal breast cancer survival: Influence of tumor characteristics and lifestyle factors? Int J Cancer. 2014; 134(12):2972–83.
21. Maalmi H, Ordóñez-Mena JM, Schöttker B, Brenner H. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: Systematic review and meta-analysis of prospective cohort studies. Eur J Cancer. 2014; 50(8):1510–21.
22. Li M, Chen P, Li J, Chu R, Xie D, Wang H. Review: The impacts of circulating 25- Hydroxyvitamin D levels on cancer patient outcomes: A systematic review and meta- analysis. J Clin Endocrinol Metab. 2014; 99(7):2327–36.
23. Mohr SB, Gorham ED, Kim J, Hofflich H, Garland CF. Meta-analysis of vitamin D sufficiency for improving survival of pa-tients with breast cancer. Anticancer Res. 2014; 34(3):1163–6.
24. Engel P, Fagherazzi G, Boutten A, Dupré T, Mesrine S, Boutron-Ruault MC, et al. Serum 25(OH) vitamin D and risk of breast cancer: A nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev. 2010; 19(9):2341–50.
25. Hossain S, Beydoun MA, Beydoun HA, Chen X, Zonderman AB WR. Vitamin D and breast cancer: A systematic review and meta-analysis of observational studies. Physiol Behav. 2018; 66(4):693–8.
26. Wang D, Vélez De-La-Paz OI, Zhai JX, Liu DW. Serum 25-hydroxyvitamin D and breast cancer risk: A meta-analysis of pro-spective studies. Tumor Biol. 2013; 34(6):3509–17.
27. Estébanez N, Gómez-Acebo I, Palazuelos C, Llorca J, Dierssen-Sotos T. Vitamin D exposure and Risk of Breast Cancer: A meta-analysis. Sci Rep. 2018; 8(1):1–13.
28. de Sousa Almeida-Filho B, De Luca Vespoli H, Pessoa EC, Machado M, Nahas- Neto J, Nahas EAP. Vitamin D deficiency is associated with poor breast cancer prognostic features in postmenopausal women. J Steroid Biochem Mol Biol. 2017; 174:284–9.
29. Abulkhair O, Saadeddin A, Makram O, Gasmelseed A, Pasha T, Shehata H, et al. Vitamin D levels and breast cancer charac-teristics: Findings in patients from Saudi Arabia. J Steroid Biochem Mol Biol. 2016; 164:106–9.
30. Kim JA, Choi R, Won H, Kim S, Choi HJ, Ryu JM, et al. Serum vitamin levels and their relationships with other biomarkers in Korean breast cancer patients. Nutrients. 2020; 12(9):1–16.
31. Feldman D, Krishnan A V., Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progres-sion. Nat Rev Cancer. 2014; 14(5):342–57.
32. Jeon SM, Shin EA. Exploring vitamin D metabolism and function in cancer. Exp Mol Med. 2018 Apr 16;50(4):1 doi: 10.1038/s12276-018-0038-9. PMID: 29657326; PMCID: PMC5938036.
33. de Almeida LF. Vitamin D Actions on Cell Differentiation, Proliferation and Inflammation. Int J Complement Altern Med. 2017; 6(5):5–7.
34. Hines SL, Jorn HKS, Thompson KM, Larson JM. Breast cancer survivors and vitamin D: A review. Nutrition. 2010; 26(3):255–62.
35. Chakraborti C. Vitamin D as a promising anticancer agent. Indian J Pharmacol. 2011; 43(2):113–20.
36. Williams JD, Aggarwal A, Swami S, Krishnan A V., Ji L, Albertelli MA, et al. Tumor autonomous effects of Vitamin D defi-ciency promote breast cancer metastasis. Endocrinology. 2016; 157(4):1341–7

Novedades
Estadísticas
Cómo citar
1.
Rus Valero, Manuela; Rus Valero, Luisa María. El Déficit de Vitamina D y su influencia en el cáncer de mama. Evidentia. 2022; 19(Supl): e14126. Disponible en: http://ciberindex.com/c/ev/e14126 [acceso: 24/09/2022]
Comentarios

DEJA TU COMENTARIO     VER 0 COMENTARIOS

Normas y uso de comentarios


Hay un total de 0 comentarios


INTRODUCIR NUEVO COMENTARIO

Para enviar un comentario, rellene los campos situados debajo. Recuerde que es obligatorio indicar un nombre y un email para enviar su comentario (el email no sera visible en el comentario).

Nombre:
e-mail:
Comentario: